Technique of transurethral needle core biopsy to confirm invasive bladder cancer staging

Similar documents
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Glossary of Terms Primary Urethral Cancer

Staging and Grading Last Updated Friday, 14 November 2008

Symptoms, Diagnosis and Classification

Diagnosis and classification

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

Bladder Cancer Guidelines

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

Radical Cystectomy Often Too Late? Yes, But...

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

3.1 Investigations for Patients Presenting with Haematuria Table 1

BLADDER CANCER: PATIENT INFORMATION

BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR

Information for Patients. Primary urethral cancer. English

A215- Urinary bladder cancer tissues

Urology An introduction to cut up DR J R GOEPEL

EAU GUIDELINES POCKET EDITION 3

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature

A patient with recurrent bladder cancer presents with the following history:

Carcinoma of the Urinary Bladder Histopathology

When to Integrate Surgery for Metatstatic Urothelial Cancers

Urological Tumours 1 Kidney tumours 2 Bladder tumours

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Trans Urethral Resection of Bladder Tumour (TURBT) Department of Urology Information for Patients

Harry W. Herr and S. Machele Donat Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Information for Patients. Bladder Cancer. English

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do?

Plasmacytoid Variant Urothelial Carcinoma: Diagnostic and Grossing Challenges. Kailyn Gibson MS, PA-ASCP, Congli Wang, MD

Urinary Bladder, Ureter, and Renal Pelvis

MEDitorial March Bladder Cancer

PROFESSIONAL SKILLS 1 3RD YEAR SEMESTER 6 RADIOGRAPHY. THE URINARY SYSTEM Uz. Fatema shmus aldeen Tel

UNDERSTANDING BLADDER CANCER

Types of bladder cancer

CYSVIEW. CONFIDENCE AT FIRST SIGHT

The pathology of bladder cancer

Guidelines for the Management of Bladder Cancer

Attachment #2 Overview of Follow-up

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

American Journals of Cancer Case Reports. A Rare Case of Rectal Metastasis from Sarcomatoid Variant of Urothelial Carcinoma: A Case Report

Attachment #2 Overview of Follow-up

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

THE CLASSIFICATION OF BLADDER TUMOURS

Advanced Pathophysiology Unit 7: Renal-Urologic Page 1 of 6

Cervical cancer presentation

ATinyIncredibleUrethralCarcinomaDimensionmaybeDeceptiveACaseReport

Large blocks in prostate and bladder pathology

Prostate Overview Quiz

Prostate Case Scenario 1

The effectiveness of ultrasound in the diagnosis of bladder Muhimbili National Hospital, Dar es Salaam, Tanzania

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate

Bladder Cancer Early Detection, Diagnosis, and Staging

90% of bladder tumours are transitional cell carcinoma (TCC), the remaining 10% of cases are squamous cell carcinoma, adenocarcinoma and sarcoma.

Immunohistochemical determinations in evaluating the prognostic in patient with urinary bladder tumors

Bladder Cancer Diagnostic Tests

Citation International journal of urology (2. Right which has been published in final f

ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA

Kidney, Bladder and Prostate Neoplasia. David Bingham MD

BLADDER CANCER CONTENT CREATED BY. Learn more at

Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder

INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER

UROTHELIAL CELL CANCER


Haematuria and Bladder Cancer

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

CADET SM BRAF MUTATION DETECTION ASSAY

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy


Care of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)

Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)

Neoplasms of the Prostate and Bladder

Primary Squamous Cell Carcinoma Of Kidney - A Case Report And Review Of Literature.

Audit of split-bolus CT urography for the investigation of haematuria over a 12 month period at two district general hospitals

250 CASES OF CARCINOMA OF URINARY BLADDER A PRELIMINARY REVIEW

Clinical Value of C-reactive Protein and Erythrocyte Sedimentation Rate in Advanced Bladder Cancer

KEYWORDS Bladder cancer, Transitional cell carcinoma, Magnetic resonance imaging, staging, Tumor node metastasis

Collection of Recorded Radiotherapy Seminars

Original Article APMC-276

Cystoscopy in children presenting with hematuria should not be overlooked

Renal tumors of adults

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity

BLADDER CANCER EPIDEMIOLOGY

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:

Bladder Case # 1. Principal Diagnosis: Bladder Tumor, Suspect Transitional Cell Carcinoma. Secondary Diagnoses: 1. Hypertension. 2. Hyperlipidemia.

Transcription:

Clinical research Technique of transurethral needle core biopsy to confirm invasive bladder cancer staging Piotr Chłosta 1, rtur. ntoniewicz 2, Tomasz Szopiński 2, Jakub Dobruch 2, ndrzej orówka 2 1Department of Urology, Institute of Oncology, Kielce, Poland 2Department of Urology, Centre of Postgraduate Urology Education, Postgraduate University, Warsaw, Poland Submitted: 23 pril 2009 ccepted: 4 May 2009 rch Med Sci 2010; 6, 3: 388-392 DOI: 10.5114/aoms.2010.14260 Copyright 2010 Termedia & anach Corresponding author: Piotr L. Chłosta, MD, PhD, FEU Department of Urology Institute of Oncology rtwinskiego 3 25-734 Kielce, Poland Phone: +48 41 367 47 74 Fax: +48 41 367 47 73 E-mail: piotr.chlosta@onkol.kielce.pl bstract Introduction: Transurethral, cystoscopically-guided needle core biopsy (TUcorexT) seems to be a less invasive diagnostic method than transurethral resection (TURT) offering a simple way to confirm cancer infiltration of the bladder. The aim of this study was to assess the technique of TUcorexT in the diagnosis of bladder cancer infiltrating the detrusor muscle. Material and methods: In every 96 pts the suspicion of invasive bladder cancer (IC) was evaluated on the basis of radiological examinations, cystoscopy and bimanual examination. TUcorexT were performed using a rigid cystoscope with a direct working channel and tru-cut automatic (COOK Quick-Core iopsy- Needle) 18 G/480 mm needle or self construction tru-cut 16 G/400 mm needle, adapted to work with a standard biopsy gun. t least three cores were taken in each patient, followed by regular TURT. Results: There were no complications of the bladder biopsy procedure. The average size of cores was 15 mm (8-17 mm). In every case TUcorexT revealed muscle infiltration and was in agreement with all microscopic examinations of TURT. Conclusions: TUcorexT in cases of clear suspicion of invasive bladder cancer is a simple, short and safe procedure which makes it possible to collect reliable material for microscopic examination. TUcorexT is less invasive than standard TURT only in diagnosis and staging of invasive tumours, and seems to be effective in selected cases to confirm malignancy before radical cystectomy. Key words: invasive bladder cancer, tru-cut biopsy, staging. Introduction The most fundamental tool used to distinguish superficial and muscle invasive bladder cancer (Ca) is properly performed transurethral resection of the bladder tumour (TURT). s is widely accepted, in TURT material should be taken separately from the tumour, its margins and the bottom [1, 2]. Diagnosis of invasive bladder cancer (IC) is usually not difficult. Infiltration of bladder detrusor revealed by histopathological examination (H-P) of the TURT specimen differentiates the Ca character. However, in some patients with advanced disease, clinical signs known before TURT may strongly suggest the presence of muscle invasive tumour. These are the results of imaging tools, bimanual examination and cystoscopy [3, 4]. Prominent infiltration may be expressed in particular by hydronephrosis, which may result from deep infiltration of the intramural part of the ureter

Technique of transurethral needle core biopsy to confirm invasive bladder cancer staging and may be found in ultrasound scan of the abdomen (TUS), intravenous urography (IVU) or computed tomography (CT) [5]. Transurethral resection of the bladder tumour is then carried out to confirm the invasive character of Ca, but histopathological examination may reveal only cancer cells without muscle tissue. Nevertheless, imaging procedures, especially CT, carried out before TURT allow us to anticipate the presence of IC. The question is whether there is any possibility of TURT replacement in patients who present with strong suspicion of invasive character of bladder tumour revealed by clinical signs, especially by TUS, IVU or CT, and who are potential candidates for radical treatment. The aim of this study is to present the technique of bladder tumour transurethral core biopsy (TUcorexT) in the diagnosis of bladder cancer infiltrating detrusor muscle, which can replace diagnostic TURT of IC patients. Material and methods Ninety-six patients (87 men and 9 women) aged between 43 and 79 years (mean age 65 years), who presented with locally advanced, extensive bladder tumour suggested by TUS and CT, were included in the study. In 72 patients, the above-mentioned imaging examinations were carried out due to haematuria only, whereas there were another 14 patients with haematuria and lower urinary tract symptoms (frequency, painful micturition; LUTS), 1 patient with LUTS only and 9 experienced lumbar pain. TUS, IVU and CT revealed unilateral or bilateral hydronephrosis associated with bladder tumour in 51 patients. ll patients were potential candidates for radical cystectomy if the invasive character of the tumour could be confirmed. The patients were subjected to TUcorexT just before the standard TURT. The procedures were performed under local spinal anaesthesia and were preceded by urinary bladder and urethra detailed endoscopic examination. Tru-cut 16 G, 400 mm in length (self-made) or 18 G, 480 mm in length (COOK Quick-Core iopsy-needle) needles put into the biopsy gun (ard Magnum Instrument MG1522) were used to carry out biopsy of the bladder tumour (Figure 1). The needle was speared superficially into the tumour and the biopsy gun was released (Figure 2). t least three cores were taken in each patient, followed by regular TURT. Pathological assessment of tissue cores and TURT specimens was done after standard preparation and haematoxylin-eosin staining. In all patients it was possible to take tissue cores. ll tumours had exophytic character. The most favourable location of the tumour in terms of the biopsy procedure was the posterior and lateral walls of the bladder. ll patients were diagnosed with IC and subjected to radical cystectomy. The specimens were then routinely evaluated. Comparison of histopathological assessment of tissue cores, TURT and radical cystectomy specimens was done to evaluate the clinical significance of TUcorexT. The type and the grade of the tumour were analysed. ll data were collected after local ethics committee approval and all patients signed informed consent previously accepted by the committee. Results The quality of all tissue cores gained by TUcorexT was sufficient to carry out a reliable histopathological assessment. Length of tissue cores ranged from 8 mm to 17 mm (mean length 15 mm). Due to the bladder tumour biopsy, transitional cell carcinoma (TCC), squamous cell carcinoma (SCC) and adenocarcinoma were diagnosed in 92, 3 and 1 patient, respectively. In 12 patients among those with TCC, SCC transformation was also found. TCC grade was G2 and G3 in 31 and 49 patients, respectively. SCC and C grades were assessed as G2 in all cases. mong patients diagnosed with TCC with SCC transformation, G2 Figure 1. Instruments for transurethral, cystoscopically-guided needle core biopsy (TUcorexT) () and the way of their usage () rch Med Sci 3, June / 2010 389

Piotr Chłosta, rtur. ntoniewicz, Tomasz Szopiński, Jakub Dobruch, ndrzej orówka Figure 2. Endoscopic view of transurethral, cystoscopically-guided needle core biopsy (TUcorexT). the needle before puncturing the right bladder wall tumour, the status after the biopsy grade in 2 cases and G3 grade in 10 cases were found (Table I). In all patients muscle infiltration was revealed by histopathological examination of tissue cores (Figure 3). Histopathological analysis of TURT specimens was in complete accordance with previous tissue core assessment in terms of the type and the grade of bladder cancer. Muscle invasion by cancer cells was found in all specimens. There were no complications specifically associated with the biopsy procedure. There was also no need for coagulation of the spear area on the surface of the tumour. Discussion The fundamental tool used to evaluate Ca character (to differentiate between superficial and muscle invasive bladder tumour) is properly carried out TURT and histopathological examination of the specimen [1, 2]. Clinical staging by imaging tools Table I. The results of histopathological examination of transurethral bladder tumour biopsy cores (TUcorexT) Histopathological type Grading Number/percentage of cancer of patients TCC G2 31 32.3% G3 49 51.0% TCC/SCC G2 2 2.0% G3 10 10.5% SCC G2 3 3.2% G3 C G2 1 1.0% G3 Total 96 100% C adenomatous cancer, SCC squamous cell cancer, TCC transitional cell cancer, G grading is not unquestionable and plays only an additional role [6]. Transurethral resection of the bladder tumour is a rather invasive procedure and is associated with substantial risk of complications, especially in regard to extensive bladder tumours [7]. In some patients, muscle infiltration of bladder tumour may be suspected during cystoscopy (plane tumour with wide base and no flocks on its surface, inflexibility of tumour infiltrating the bladder wall). Hence, collecting sufficient tissue material to assess the quantity of muscle tissue in a less invasive manner is required before eventual radical cystectomy. It seems that TUcorexT is a favourable option in patients who present with bladder tumour and who are highly suspected to have muscle involvement due to imaging procedures (TUS, IVU) carried out before cystoscopy [8]. There were no complications specifically associated with the transurethral core biopsy procedure. It is not possible to exclude such a risk because the biopsy was followed by regular TURT, which would mask their presence. However, one would not envisage major complications with a few punctures. The risk of cancer cell spread as a consequence of TUcorexT remains to be elucidated. However, it does not preclude carrying out prostate biopsy in men with high suspicion of prostate cancer [9]. It is conceivable that the risk of implantation of cancer cells outside the bladder wall during TUcorexT should not be greater than in the case of extensive TURT. The idea of using TUcorexT in the diagnosis of muscle invasive tumours is unique. Trans - cutaneous needle core biopsy under ultrasound control and transurethral core biopsy using a nephroscope carried out in patients with locally advanced bladder tumour subjected to neoadjuvant treatment were presented by Hoshi et al. [10]. It 390 rch Med Sci 3, June / 2010

Technique of transurethral needle core biopsy to confirm invasive bladder cancer staging Figure 3. The bladder tumour biopsy core prepared for histopathological examination (), histopathological view of the invasive bladder cancer TUcorexT specimen. rrows indicate cancer cells between detrusor muscle tissue (enlarged 20, H/E] () was suggested that the biopsy allowed collection of enough tissue material to evaluate the tumour stage and the treatment results. Malmstrom et al. introduced transcutaneous bladder core biopsy carried out under CT control in patients who underwent neoadjuvant chemotherapy due to Ca in order to collect valuable amounts of tissue material [11]. The results do not suggest that diagnostic TURT would be replaced by TUcorexT in all patients presenting with Ca. It would be very difficult to find carcinoma in situ. TUcorexT would not be applied in cases of superficial Ca. On the other hand, in cases of extensive, solid, muscle infiltrating bladder tumours it allows for quick, cost-effective, efficient and less invasive collection of tissue material for histopathological examination and qualification for radical therapy. The biopsy carried out in patients subjected to TURT carried out just to confirm tumour invasiveness before radical cystectomy has obvious advantages: reduced duration of the procedure, lower probability of bladder perforation and bleeding, lack of perivesical lesions observed after TURT and the possibility of carrying out the procedure under intravenous anaesthesia and in an out-patient setting. Therefore, it is reasonable to suggest that TUcorexT, which is supposed to invade the muscle tissue, will simplify the diagnostic procedure aimed at tumour staging before radical therapy and make it easier and also less invasive. In conclusion, transurethral core biopsy of bladder tumour is indicated only in patients with large and highly suspected muscle invasive characteristics of bladder cancer. The biopsy would serve to confirm the clinical data before planned radical cystectomy. There are enough clinical data to know that the tumour infiltrates deeply into the bladder wall, but to carry out cystectomy, histological confirmation is still needed. In such cases, instead of the relatively invasive TURT, the biopsy and a few tissue cores may be sufficient to reveal bladder detrusor involvement. In patients with less advanced disease, the biopsy would not bring any benefit. Endoscopic transurethral needle core bladder tumour biopsy (TUcorexT) allows collection of sufficient amounts of tissue material for histopathological confirmation of detrusor muscle infiltration. TUcorexT bladder tumour biopsy carried out under cystoscopic control is short lasting, efficient, safe, easy to perform and less invasive than standard transurethral resection of bladder tumour (TURT) carried out in cases of extensive invasive bladder cancer (IC). References 1. Messing EM, Young T, Hunt V, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995; 45: 387-97. 2. Kolozsy Z. Histopathological self control in transurethral resection of bladder tumors. r J Urol 1991; 67: 162-4. 3. Oesterlinck W, Lobel, Jakse G, et al. European ssociation of Urology (EU) Working Group on Oncological Urology Guidelines on bladder cancer. EU 2005; 3-30 4. Husband JE, Olliff JF, Williams MP, et al. ladder cancer: staging with CT and MR imaging. Radiology 1989; 173: 435-40. 5. Chłosta P, ntoniewicz, Szopiński T, et al. Ocena porównawcza przydatności ultrasonografii przezpowło - kowej tomografii komputerowej oraz jądrowego rezonan - su magnetycznego do oceny stopnia zaawansowania raka pęcherza moczowego u chorych poddanych cystektomii radykalnej [Polish]. Urol Pol 2004; 2: 20-4. 6. Voges GE, Tauschke E, Stockle M, et al. Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. Urology 1989; 142: 972-4. rch Med Sci 3, June / 2010 391

Piotr Chłosta, rtur. ntoniewicz, Tomasz Szopiński, Jakub Dobruch, ndrzej orówka 7. Herr HW. Surgical factors in the treatment of superficial and invasive bladder cancer. Urol Clin North m 2005; 32: 157-64. 8. Chłosta P, Szopiński T, ntoniewicz, et al. Clinical significance of transurethral tru-cut biopsy in confirmation of bladder tumor invasive character. Int J Urol 2008; 15: 804-8. 9. Sachs MD, Chan T, Solomon S, Konig F, Schoenberg M. Diagnostics and diagnostic pitfalls in urothelial bladder cancer. In: Droller MJ (ed.). Urothelial tumors. C Decker Inc, London 2004; 73-91. 10. Hoshi S, Ono K, Suzuki K, et al. Trans-urethral whole layer core biopsy for detection of residual tumor after neoadjuvant therapy in invasive bladder cancer. Urol Oncol 2001; 6: 85-9. 11. Malmstrom PU, Lonnemark M, usch C, et al. Staging of bladder carcinoma by computer tomography-guided transmural core biopsy. Scand J Urol Nephrol 1993; 27: 193-8. 392 rch Med Sci 3, June / 2010